Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

Show other versions (1)

Aims: To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2years in patients with type 2 diabetes. Methods: In the 26-week the Liraglutide Effect and Action in Diabetes (LEAD)-2 core trial, patie...

Full description

Bibliographic Details
Main Authors:	Nauck, M, Frid, A, Hermansen, K, Thomsen, AB, During, M, Shah, N, Tankova, T, Mitha, I, Matthews, D
Format:	Journal article
Published:	2013

Similar Items

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
by: Nauck, M, et al.
Published: (2009)

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes
by: Nauck, M, et al.
Published: (2009)

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
by: Nauck, M, et al.
Published: (2013)

Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data
by: Frid, A, et al.
Published: (2009)

Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
by: Hermansen, K, et al.
Published: (2008)

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
by: Hermansen, K, et al.
Published: (2010)

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
by: Jendle, J, et al.
Published: (2009)

Liraglutide add-on to metformin improves postprandial glucose control compared with metformin monotherapy in patients with Type 2 diabetes: posthoc analysis of the Liraglutide Effect and Action in Diabetes (LEAD)2 study
by: Stephens, J, et al.
Published: (2014)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
by: J. Jendle, et al.
Published: (2021-12-01)

The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat
by: Jendle, J, et al.
Published: (2008)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
by: Mozhgan Dorkhan, et al.
Published: (2007-11-01)

Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
by: Thomas Nyström, et al.
Published: (2017-11-01)

Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
by: Soo Lim, et al.
Published: (2023-01-01)

Corrigendum: Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
by: Thomas Nyström, et al.
Published: (2018-02-01)

Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 diabetic patients
by: Surendra Kumar
Published: (2021-01-01)

Effects of Metformin &/or Glimepiride on Resistin Level and Related Biochemical Markers in Type 2 Diabetes Mellitus
by: Hadeel Delman Najim, et al.
Published: (2014-12-01)

Effect of hydroxychloroquine on glycemic variability in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy
by: Rajesh Rajput, et al.
Published: (2022-01-01)

Liraglutide is associated with a significantly greater improvement in glycaemic control than glimepiride in patients with highest baseline beta cell function
by: Matthews, DR, et al.
Published: (2009)

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
by: Ahrén, B, et al.
Published: (2010)

Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus
by: Subodh Kumar, et al.
Published: (2015-12-01)

Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus
by: Helena Atroch Machado, et al.
Published: (2012-07-01)

A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus
by: Tanya Tandon, et al.
Published: (2019-01-01)

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
by: Ferrannini, E, et al.
Published: (2009)

Efek Pemberian Metformin dan Metformin+Glimepiride terhadap Kadar HbA1c pada Pasien Diabetes Mellitus Tipe 2
by: Fitri Apriliany, et al.
Published: (2022-06-01)

Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
by: Natalya Vladislavovna Zaytseva, et al.
Published: (2015-06-01)

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
by: Matthews, DR, et al.
Published: (2010)

Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
by: Xie J, et al.
Published: (2019-04-01)

Expert consensus on triple combination of glimepiride, metformin, and voglibose usage in patients with type 2 diabetes mellitus in Indian settings
by: Ashok K Das, et al.
Published: (2022-01-01)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
by: Hara Kousoulakou, et al.
Published: (2017-09-01)

Urinary Metabolomic Profiling in Zucker Diabetic Fatty Rats with Type 2 Diabetes Mellitus Treated with Glimepiride, Metformin, and Their Combination
by: Yu Dong, et al.
Published: (2016-10-01)

Liraglutide Is Associated with Reduced Rates of Hypoglycemic Events Versus Glimepiride When Achieving Target HbA(1c)
by: Gough, S, et al.
Published: (2010)

Changes in prandial glucagon levels after 2 years treatment with vildagliptin or glimepiride
by: Ahren, B, et al.
Published: (2009)

Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.
by: Cheol-Young Park, et al.
Published: (2014-01-01)

A Prospective Observational Study to Compare the Efficacy and Adverse Effects of Glimepiride and Vildagliptin Added to Metformin in Type 2 Diabetes Mellitus
by: Biswanath Sharma Sarkar, et al.
Published: (2019-02-01)

Neuro, cardio, and reno protective activities of rosuvastatin in streptozotocin-induced type 2 diabetic rats undergoing treatment with metformin and glimepiride
by: Shailaja Rondi, et al.
Published: (2014-01-01)

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
by: Seung-Hwan Lee, et al.
Published: (2017-11-01)

The impact of disease stage, indicated by number of previous oral antidiabetic agents, on the clinical benefits of liraglutide in the treatment of type 2 diabetes
by: Garber, A, et al.
Published: (2011)

Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
by: Ying Liu, et al.
Published: (2017-12-01)

Assessment of Clinical Experience of Triple Drug Fixed-dose Combination of Glimepiride, Metformin and Voglibose in the Management of Type 2 Diabetes Mellitus: A Retrospective Study
by: Ganapathi Bantwal, et al.
Published: (2021-09-01)